PATENT
Attorney Docket No. 213187

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kovesdi et al.

Continuation of U.S. Patent Application No. 08/258,416

Filed: August 21, 2001

For: ADENOVECTOR PHARMACEUTICAL COMPOSITION

Art Unit: Unassigned

Examiner: Unassigned

PENDING CLAIMS AFTER ENTRY OF PRELIMINARY AMENDMENT

36. A pharmaceutical composition comprising recombinant adenoviral vectors and a pharmaceutically acceptable carrier, wherein each recombinant adenoviral vector is deficient in one or more essential gene functions of one or more regions of the adenoviral genome selected from the group consisting of the E1, E2A, and E4 regions of the adenoviral genome, and wherein the pharmaceutical composition does not contain replication-competent adenoviruses.

37. The composition of claim 36, wherein the adenoviral vector is deficient in one or more essential gene functions of E1.

38. The composition of claim 36, wherein the adenoviral vector is deficient in one or more essential gene functions of E2A.

39. The composition of claim 36, wherein the adenoviral vector is deficient in one or more essential gene functions of E4.

40. The composition of claim 36, wherein the adenoviral vector is deficient in two or more essential gene functions.

41. The composition of claim 40, wherein the adenoviral vector is deficient in one or more essential gene functions of each of the E1 and E2A regions of the adenoviral genome.

42. The composition of claim 40, wherein the adenoviral vector is deficient in one or more essential gene functions of each of the E1 and E4 regions of the adenoviral genome.

43. The composition of claim 40, wherein the adenoviral vector is deficient in one or more essential gene functions of each of the E2A and E4 regions of the adenoviral genome.

44. The composition of claim 36, wherein the adenoviral vector is deficient in one or more essential gene function of each of three regions of the adenoviral genome.

45. The composition of claim 44, wherein the adenoviral vector is deficient in one or more essential gene functions of each of the E1, E2A, and E4 regions of the adenoviral genome.

46. The composition of claim 36, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

47. The composition of claim 37, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

48. The composition of claim 38, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

49. The composition of claim 39, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

50. The composition of claim 40, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

51. The composition of claim 41, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

52. The composition of claim 42, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

53. The composition of claim 43, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

54. The composition of claim 44, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

55. The composition of claim 45, wherein the adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.